Karyopharm Therapeutics (KPTI) Assets Average (2013 - 2026)
Karyopharm Therapeutics' (KPTI) quarterly Assets Average came in at $102.3 million in Q4 2025, down 42.17% YoY from $176.9 million in Q4 2024, and up 1.76% on a QoQ basis from $100.6 million in Q3 2025.
Karyopharm Therapeutics (KPTI) Assets Average (2013 - 2026) Analysis & Trends
Karyopharm Therapeutics (KPTI) has 13 years of Assets Average data on file, last reported at $102.3 million in Q4 2025.
- Quarterly Assets Average fell 42.17% year-over-year to $102.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $102.3 million (down 42.17% YoY) and the FY2025 annual result came in at $136.4 million, down 32.61% from the prior year.
- Assets Average grew to $102.3 million in Q4 2025, from $100.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $342.0 million in Q1 2023 to a low of $100.6 million in Q3 2025.
- A 5-year average of $235.3 million and a median of $262.8 million in 2021 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average increased 16.42% — and 2025, when it slumped 50.15%.
- Tracing KPTI's Assets Average over 5 years: stood at $279.7 million in 2021, then rose by 5.36% to $294.7 million in 2022, then dropped by 13.4% to $255.2 million in 2023, then plunged by 30.66% to $176.9 million in 2024, then plunged by 42.17% to $102.3 million in 2025.
- The last three Assets Average figures came in at $102.3 million (Q4 2025), $100.6 million (Q3 2025), and $116.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Karyopharm Therapeutics | 53.25 Mn | 53.25 Mn | 32.35 Mn | 109.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109.87 Mn |
| Dec 31, 2025 | 102.32 Mn |
| Sep 30, 2025 | 100.56 Mn |
| Jun 30, 2025 | 116.30 Mn |
| Mar 31, 2025 | 146.06 Mn |
| Dec 31, 2024 | 176.95 Mn |
| Sep 30, 2024 | 201.73 Mn |
| Jun 30, 2024 | 209.22 Mn |
| Mar 31, 2024 | 222.45 Mn |
| Dec 31, 2023 | 255.20 Mn |
| Sep 30, 2023 | 283.90 Mn |
| Jun 30, 2023 | 311.82 Mn |
| Mar 31, 2023 | 341.99 Mn |
| Dec 31, 2022 | 294.70 Mn |
| Sep 30, 2022 | 243.86 Mn |
| Jun 30, 2022 | 275.26 Mn |
| Mar 31, 2022 | 299.67 Mn |
| Dec 31, 2021 | 279.70 Mn |
| Sep 30, 2021 | 270.33 Mn |
| Jun 30, 2021 | 280.74 Mn |